The latest information on the domestic launch progress and market price of obeticholic acid in 2024

Obeticholic acid (Obeticholic Acid), as an innovative farnesoidX receptor agonist, has attracted much attention in the field of global liver disease treatment in recent years. Currently, the drug has been approved in European and American countries for the treatment of primary biliary cholangitis (PBC). At the same time, its potential in the treatment of non-alcoholic steatohepatitis (NASH) is gradually recognized. Many domestic patients are very concerned about obeticholic acid. This article will detail its domestic launch progress and latest market price.

1. New progress in domestic listing in 2024

Entering2024, obeticholic acid has made a significant breakthrough in the domestic launch process. The latest news shows that Chia Tai Tianqing Pharmaceutical Group Co., Ltd., a subsidiary of China Biopharmaceuticals, has officially submitted a marketing application for obeticholic acid tablets to the China National Medical Products Administration and has been accepted. The drug is primarily intended for the treatment of adult patients with primary biliary cholangitis, particularly those who have an inadequate response to or intolerance to ursodeoxycholic acid (UDCA). In addition, obeticholic acid also shows broad application prospects in the field of NASH treatment, and is expected to further expand its domestic market.

Although obeticholic acid has not yet been officially launched in China, its research and development progress and successful acceptance of its marketing application have undoubtedly brought new hope to domestic liver disease patients. As the approval process continues to advance, it is expected that obeticholic acid will officially enter the domestic market in the near future, providing more and better treatment options for patients with liver diseases.

2. Latest market selling price

Currently, there are both original research versions and affordable generic versions of obeticholic acid on the market, with certain price differences. Original medicines are more expensive, ranging from several thousand or even tens of thousands of yuan per box. Generic drugs are relatively close to the people. For example, the version produced by Mylan in India (10mg100 tablets) sells for about 900 yuan, and the version produced by Laos and ASEAN (5mg30 tablets) sells for about 600 yuan. Patients should consider their own needs and financial situation when choosing, but be sure to purchase through guaranteed formal channels. It is worth noting that the market selling price may be affected by multiple factors such as exchange rate, market demand and policy environment. Therefore, the specific selling price must be based on the latest real-time price announced by the pharmaceutical manufacturer.

To sum up, the domestic launch of obeticholic acid is progressing steadily, and the market is full of expectations for it. With the approval process completed and the official launch date approaching, it is believed that obeticholic acid will soon enter the domestic market, bringing new treatment hope to the majority of liver disease patients.